Published in J Virol on December 24, 2008
Pre-existing immunity against swine-origin H1N1 influenza viruses in the general human population. Proc Natl Acad Sci U S A (2009) 4.47
Wide prevalence of heterosubtypic broadly neutralizing human anti-influenza A antibodies. Clin Infect Dis (2011) 2.12
Animal Models for Influenza Virus Pathogenesis and Transmission. Viruses (2010) 1.88
Influenza virus hemagglutinin stalk-based antibodies and vaccines. Curr Opin Virol (2013) 1.69
Conserved epitopes of influenza A virus inducing protective immunity and their prospects for universal vaccine development. Virol J (2010) 1.39
Avian influenza A H5N1 virus: a continuous threat to humans. Emerg Microbes Infect (2012) 1.30
Preparation, characterization, and immunogenicity in mice of a recombinant influenza H5 hemagglutinin vaccine against the avian H5N1 A/Vietnam/1203/2004 influenza virus. Vaccine (2009) 1.14
Combination therapy using chimeric monoclonal antibodies protects mice from lethal H5N1 infection and prevents formation of escape mutants. PLoS One (2009) 1.10
Novel vaccines against influenza viruses. Virus Res (2011) 1.04
Identification and structural characterization of a broadly neutralizing antibody targeting a novel conserved epitope on the influenza virus H5N1 hemagglutinin. J Virol (2012) 1.00
A simple slot blot for the detection of virtually all subtypes of the influenza A viral hemagglutinins using universal antibodies targeting the fusion peptide. Nat Protoc (2010) 0.98
Intranasal delivery of an IgA monoclonal antibody effective against sublethal H5N1 influenza virus infection in mice. Clin Vaccine Immunol (2010) 0.96
Virus-like particles as universal influenza vaccines. Expert Rev Vaccines (2012) 0.93
Cold-adapted pandemic 2009 H1N1 influenza virus live vaccine elicits cross-reactive immune responses against seasonal and H5 influenza A viruses. J Virol (2012) 0.93
Mechanism of neutralization of herpes simplex virus by antibodies directed at the fusion domain of glycoprotein B. J Virol (2013) 0.92
Identification of a highly conserved H1 subtype-specific epitope with diagnostic potential in the hemagglutinin protein of influenza A virus. PLoS One (2011) 0.90
The epitope and neutralization mechanism of AVFluIgG01, a broad-reactive human monoclonal antibody against H5N1 influenza virus. PLoS One (2012) 0.89
Roles of the hemagglutinin of influenza A virus in viral entry and development of antiviral therapeutics and vaccines. Protein Cell (2010) 0.89
A VLP vaccine induces broad-spectrum cross-protective antibody immunity against H5N1 and H1N1 subtypes of influenza A virus. PLoS One (2012) 0.88
Increased immunogenicity and protective efficacy of influenza M2e fused to a tetramerizing protein. PLoS One (2012) 0.88
Epitope specificity of anti-HA2 antibodies induced in humans during influenza infection. Influenza Other Respir Viruses (2012) 0.87
Unraveling of a neutralization mechanism by two human antibodies against conserved epitopes in the globular head of H5 hemagglutinin. J Virol (2012) 0.86
H5N1 whole-virus vaccine induces neutralizing antibodies in humans which are protective in a mouse passive transfer model. PLoS One (2011) 0.83
Properties and therapeutic efficacy of broadly reactive chimeric and humanized H5-specific monoclonal antibodies against H5N1 influenza viruses. Antimicrob Agents Chemother (2011) 0.82
Immunogenicity of low-pH treated whole viral influenza vaccine. Virology (2011) 0.81
Cross-reactive human B cell and T cell epitopes between influenza A and B viruses. Virol J (2013) 0.81
A high-affinity CDR-grafted antibody against influenza A H5N1 viruses recognizes a conserved epitope of H5 hemagglutinin. PLoS One (2014) 0.80
A novel subnucleocapsid nanoplatform for mucosal vaccination against influenza virus that targets the ectodomain of matrix protein 2. J Virol (2013) 0.80
Long-lasting protective antiviral immunity induced by passive immunotherapies requires both neutralizing and effector functions of the administered monoclonal antibody. J Virol (2010) 0.80
The self/nonself issue: A confrontation between proteomes. Self Nonself (2010) 0.79
Prospects of HA-based universal influenza vaccine. Biomed Res Int (2015) 0.79
Cross-protective immune responses elicited by live attenuated influenza vaccines. Yonsei Med J (2013) 0.79
Principles underlying rational design of live attenuated influenza vaccines. Clin Exp Vaccine Res (2012) 0.78
Passive immune neutralization strategies for prevention and control of influenza A infections. Immunotherapy (2012) 0.78
Immunization with a hemagglutinin-derived synthetic peptide formulated with a CpG-DNA-liposome complex induced protection against lethal influenza virus infection in mice. PLoS One (2012) 0.78
Monoclonal antibody specific to HA2 glycopeptide protects mice from H3N2 influenza virus infection. Vet Res (2015) 0.78
Oral Delivery of a Novel Attenuated Salmonella Vaccine Expressing Influenza A Virus Proteins Protects Mice against H5N1 and H1N1 Viral Infection. PLoS One (2015) 0.77
Construction of a chimeric secretory IgA and its neutralization activity against avian influenza virus H5N1. J Immunol Res (2014) 0.77
Receptor-binding domains of spike proteins of emerging or re-emerging viruses as targets for development of antiviral vaccines. Emerg Microbes Infect (2012) 0.77
LEAPS therapeutic vaccines as antigen specific suppressors of inflammation in infectious and autoimmune diseases. J Vaccines Vaccin (2012) 0.77
Protein engineering strategies for the development of viral vaccines and immunotherapeutics. FEBS Lett (2013) 0.76
A Fusion Protein Based on the Second Subunit of Hemagglutinin of Influenza A/H2N2 Viruses Provides Cross Immunity. Acta Naturae (2016) 0.75
Cell penetrable human scFv specific to middle domain of matrix protein-1 protects mice from lethal influenza. Viruses (2015) 0.75
Inactivated Influenza Vaccine That Provides Rapid, Innate-Immune-System-Mediated Protection and Subsequent Long-Term Adaptive Immunity. MBio (2015) 0.75
Globular Head-Displayed Conserved Influenza H1 Hemagglutinin Stalk Epitopes Confer Protection against Heterologous H1N1 Virus. PLoS One (2016) 0.75
Structure of the haemagglutinin membrane glycoprotein of influenza virus at 3 A resolution. Nature (1981) 24.17
Avian influenza A (H5N1) infection in humans. N Engl J Med (2005) 12.95
Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States. JAMA (2006) 8.06
Evolution of H5N1 avian influenza viruses in Asia. Emerg Infect Dis (2005) 6.99
Avian flu: isolation of drug-resistant H5N1 virus. Nature (2005) 6.66
Structure of the hemagglutinin precursor cleavage site, a determinant of influenza pathogenicity and the origin of the labile conformation. Cell (1998) 3.69
Prophylactic and therapeutic efficacy of human monoclonal antibodies against H5N1 influenza. PLoS Med (2007) 3.63
Epidemiology of WHO-confirmed human cases of avian influenza A(H5N1) infection. Wkly Epidemiol Rec (2006) 3.52
Virulence may determine the necessary duration and dosage of oseltamivir treatment for highly pathogenic A/Vietnam/1203/04 influenza virus in mice. J Infect Dis (2005) 2.72
Introduction of intersubunit disulfide bonds in the membrane-distal region of the influenza hemagglutinin abolishes membrane fusion activity. Cell (1992) 2.47
Epitope mapping of the hemagglutinin molecule of a highly pathogenic H5N1 influenza virus by using monoclonal antibodies. J Virol (2007) 2.39
Endocytosis of influenza viruses. Microbes Infect (2004) 2.38
Pre- and postexposure prophylaxis of Ebola virus infection in an animal model by passive transfer of a neutralizing human antibody. J Virol (2002) 2.31
The growth and potential of human antiviral monoclonal antibody therapeutics. Nat Biotechnol (2007) 2.19
Passive immunoprophylaxis and therapy with humanized monoclonal antibody specific for influenza A H5 hemagglutinin in mice. Respir Res (2006) 2.15
Avian influenza A (H5N1). J Clin Virol (2005) 1.90
Prospects for universal influenza virus vaccine. Emerg Infect Dis (2006) 1.68
Antibodies for the prevention and treatment of viral diseases. Antiviral Res (2000) 1.56
Influenza type A virus escape mutants emerge in vivo in the presence of antibodies to the ectodomain of matrix protein 2. J Virol (2005) 1.49
Therapeutic potential of a fully human monoclonal antibody against influenza A virus M2 protein. Antiviral Res (2008) 1.30
Monoclonal antibodies recognizing EVETPIRN epitope of influenza A virus M2 protein could protect mice from lethal influenza A virus challenge. Immunol Lett (2004) 1.26
Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant. Virology (2008) 1.25
Antibodies induced by the HA2 glycopolypeptide of influenza virus haemagglutinin improve recovery from influenza A virus infection. J Gen Virol (2008) 1.21
Antibodies specific to the HA2 glycopolypeptide of influenza A virus haemagglutinin with fusion-inhibition activity contribute to the protection of mice against lethal infection. J Gen Virol (2007) 1.07
Localization, synthesis, and activity of an antigenic site on influenza virus hemagglutinin. Proc Natl Acad Sci U S A (1983) 1.05
Fusion of influenza virus with the endosomal membrane is inhibited by monoclonal antibodies to defined epitopes on the hemagglutinin. Virus Res (1998) 1.04
Effect of formalin, beta-propiolactone, merthiolate, and ultraviolet light upon influenza virus infectivity chicken cell agglutination, hemagglutination, and antigenicity. Appl Microbiol (1970) 1.03
Protective efficacy of several vaccines against highly pathogenic H5N1 avian influenza virus under experimental conditions. Vaccine (2008) 1.00
Development of an antigen-capture ELISA for detection of H7 subtype avian influenza from experimentally infected chickens. J Virol Methods (2007) 0.97
A hemagglutinin-based multipeptide construct elicits enhanced protective immune response in mice against influenza A virus infection. Immunol Lett (1998) 0.92
An antibody which binds to the membrane-proximal end of influenza virus haemagglutinin (H3 subtype) inhibits the low-pH-induced conformational change and cell-cell fusion but does not neutralize virus. J Gen Virol (1998) 0.89
IgG neutralization of type A influenza viruses and the inhibition of the endosomal fusion stage of the infectious pathway in BHK cells. Virology (1993) 0.89
A monoclonal antibody specific to the HA2 glycoprotein of influenza A virus hemagglutinin that inhibits its fusion activity reduces replication of the virus. Acta Virol (2003) 0.88
[Laboratory biosafety manual. World Health Organization]. Ann Ist Super Sanita (1995) 0.88
Antigenic glycopolypeptides HA1 and HA2 of influenza virus haemagglutinin. IV. Immunogenic properties of separated haemagglutinin glycopolypeptides. Acta Virol (1979) 0.86
Influenza A virus-specific H-2d restricted cross-reactive cytotoxic T lymphocyte epitope(s) detected in the hemagglutinin HA2 subunit of A/Udorn/72. Virology (1995) 0.83
Characterization of a previously unidentified viral protein in porcine circovirus type 2-infected cells and its role in virus-induced apoptosis. J Virol (2005) 1.92
Betanodavirus B2 is an RNA interference antagonist that facilitates intracellular viral RNA accumulation. J Virol (2006) 1.30
The ORF3 protein of porcine circovirus type 2 is involved in viral pathogenesis in vivo. J Virol (2006) 1.26
Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant. Virology (2008) 1.25
Neutralizing epitopes of influenza virus hemagglutinin: target for the development of a universal vaccine against H5N1 lineages. J Virol (2010) 1.16
Resistance to anti-influenza drugs: adamantanes and neuraminidase inhibitors. Expert Rev Anti Infect Ther (2006) 1.16
Immunological characterization of the spike protein of the severe acute respiratory syndrome coronavirus. J Clin Microbiol (2004) 1.13
Development of epitope-blocking ELISA for universal detection of antibodies to human H5N1 influenza viruses. PLoS One (2009) 1.12
GM-CSF and IL-4 stimulate antibody responses in humanized mice by promoting T, B, and dendritic cell maturation. J Immunol (2012) 1.11
Combination therapy using chimeric monoclonal antibodies protects mice from lethal H5N1 infection and prevents formation of escape mutants. PLoS One (2009) 1.10
Detection of H5 avian influenza viruses by antigen-capture enzyme-linked immunosorbent assay using H5-specific monoclonal antibody. Clin Vaccine Immunol (2007) 1.09
RING-H2 protein WSSV249 from white spot syndrome virus sequesters a shrimp ubiquitin-conjugating enzyme, PvUbc, for viral pathogenesis. J Virol (2005) 1.09
Gastrointestinal delivery of baculovirus displaying influenza virus hemagglutinin protects mice against heterologous H5N1 infection. J Virol (2010) 1.08
Identification of white spot syndrome virus latency-related genes in specific-pathogen-free shrimps by use of a microarray. J Virol (2003) 1.08
Baculovirus as vaccine vectors. Curr Gene Ther (2010) 1.03
Characterization of an isotype-dependent monoclonal antibody against linear neutralizing epitope effective for prophylaxis of enterovirus 71 infection. PLoS One (2012) 1.02
White spot syndrome virus open reading frame 222 encodes a viral E3 ligase and mediates degradation of a host tumor suppressor via ubiquitination. J Virol (2006) 1.01
Expression of hemagglutinin protein from the avian influenza virus H5N1 in a baculovirus/insect cell system significantly enhanced by suspension culture. BMC Microbiol (2006) 1.01
Identification and characterization of a new E3 ubiquitin ligase in white spot syndrome virus involved in virus latency. Virol J (2008) 0.99
Development of an antigen-capture ELISA for detection of H7 subtype avian influenza from experimentally infected chickens. J Virol Methods (2007) 0.97
The ORF3 protein of porcine circovirus type 2 interacts with porcine ubiquitin E3 ligase Pirh2 and facilitates p53 expression in viral infection. J Virol (2007) 0.97
Characterization of ORF89--a latency-related gene of white spot syndrome virus. Virology (2004) 0.96
Development of a Western blot assay for detection of antibodies against coronavirus causing severe acute respiratory syndrome. Clin Diagn Lab Immunol (2004) 0.96
Rapid detection of H5N1 subtype influenza viruses by antigen capture enzyme-linked immunosorbent assay using H5- and N1-specific monoclonal antibodies. Clin Vaccine Immunol (2009) 0.96
Retracted Baculovirus surface-displayed hemagglutinin of H5N1 influenza virus sustains its authentic cleavage, hemagglutination activity, and antigenicity. Biochem Biophys Res Commun (2007) 0.95
Characterization of monoclonal antibody against SARS coronavirus nucleocapsid antigen and development of an antigen capture ELISA. J Virol Methods (2005) 0.95
Neuroendocrine-immune interactions in fish: a role for interleukin-1. Vet Immunol Immunopathol (2002) 0.94
Immunohistochemical detection of Influenza virus infection in formalin-fixed tissues with anti-H5 monoclonal antibody recognizing FFWTILKP. J Virol Methods (2008) 0.93
Identification of a novel shrimp protein phosphatase and its association with latency-related ORF427 of white spot syndrome virus. FEBS Lett (2004) 0.93
Display of VP1 on the surface of baculovirus and its immunogenicity against heterologous human enterovirus 71 strains in mice. PLoS One (2011) 0.93
Attenuation of human enterovirus 71 high-replication-fidelity variants in AG129 mice. J Virol (2014) 0.93
WSSV ie1 promoter is more efficient than CMV promoter to express H5 hemagglutinin from influenza virus in baculovirus as a chicken vaccine. BMC Microbiol (2008) 0.92
Baculovirus vector as a delivery vehicle for influenza vaccines. Expert Rev Vaccines (2009) 0.92
Cross-protective efficacy of bivalent recombinant baculoviral vaccine against heterologous influenza H5N1 challenge. Vaccine (2013) 0.92
Membrane association of greasy grouper nervous necrosis virus protein A and characterization of its mitochondrial localization targeting signal. J Virol (2004) 0.91
Prophylactic and therapeutic efficacy of a chimeric monoclonal antibody specific for H5 haemagglutinin against lethal H5N1 influenza. Antivir Ther (2009) 0.91
Characterization and specificity of the linear epitope of the enterovirus 71 VP2 protein. Virol J (2012) 0.91
Dissection of double-stranded RNA binding protein B2 from betanodavirus. J Virol (2007) 0.90
Identification of nucleolus localization signal of betanodavirus GGNNV protein alpha. Virology (2003) 0.90
Sequestration and protection of double-stranded RNA by the betanodavirus b2 protein. J Virol (2006) 0.90
Localization of VP28 on the baculovirus envelope and its immunogenicity against white spot syndrome virus in Penaeus monodon. Virology (2009) 0.89
Induction of caspase-dependent apoptosis by betanodaviruses GGNNV and demonstration of protein alpha as an apoptosis inducer. Virology (2003) 0.88
Baculovirus-mediated promoter assay and transcriptional analysis of white spot syndrome virus orf427 gene. Virol J (2005) 0.88
ORF3 of porcine circovirus 2 enhances the in vitro and in vivo spread of the of the virus. Virology (2010) 0.86
Attenuation of porcine circovirus 2 in SPF piglets by abrogation of ORF3 function. Virology (2008) 0.86
Effective intranasal therapeutics and prophylactics with monoclonal antibody against lethal infection of H7N7 influenza virus. Antiviral Res (2013) 0.86
Complementary monoclonal antibody-based dot ELISA for universal detection of H5 avian influenza virus. BMC Microbiol (2010) 0.86
Evaluation of a safe and sensitive Spike protein-based immunofluorescence assay for the detection of antibody responses to SARS-CoV. J Immunol Methods (2004) 0.85
A novel peptide ELISA for universal detection of antibodies to human H5N1 influenza viruses. PLoS One (2011) 0.85
Porcine circovirus type 2 induces the activation of nuclear factor kappa B by IkappaBalpha degradation. Virology (2008) 0.85
Natural compounds inhibiting the replication of Porcine reproductive and respiratory syndrome virus. Antiviral Res (2012) 0.85
Vaccination of ducks with recombinant outer membrane protein (OmpA) and a 41 kDa partial protein (P45N') of Riemerella anatipestifer. Vet Microbiol (2002) 0.85
Viral ubiquitin ligase WSSV222 is required for efficient white spot syndrome virus replication in shrimp. J Gen Virol (2009) 0.84
Immune predictors of cancer progression. Immunol Res (2012) 0.84
Novel immunofluorescence assay using recombinant nucleocapsid-spike fusion protein as antigen to detect antibodies against severe acute respiratory syndrome coronavirus. Clin Diagn Lab Immunol (2005) 0.84
Oral vaccination of baculovirus-expressed VP28 displays enhanced protection against White Spot Syndrome Virus in Penaeus monodon. PLoS One (2011) 0.83
RNA polymerase I-driven reverse genetics system for enterovirus 71 and its implications for vaccine production. Virol J (2012) 0.83
Avian encephalomyelitis virus nonstructural protein 2C induces apoptosis by activating cytochrome c/caspase-9 pathway. Virology (2004) 0.82
Monoclonal Antibody Targeting Neutralizing Epitope on H5N1 Influenza Virus of Clade 1 and 0 for Specific H5 Quantification. Influenza Res Treat (2013) 0.82
Induction of protective immune responses against EV71 in mice by baculovirus encoding a novel expression cassette for capsid protein VP1. Antiviral Res (2012) 0.82
Identification of novel attenuated Salmonella Enteritidis mutants. FEMS Immunol Med Microbiol (2008) 0.81
Intranasal immunization of baculovirus displayed hemagglutinin confers complete protection against mouse adapted highly pathogenic H7N7 reassortant influenza virus. PLoS One (2013) 0.81
Avian encephalomyelitis virus induces apoptosis via major structural protein VP3. Virology (2002) 0.81
Porcine circovirus type 2 ORF3 protein competes with p53 in binding to Pirh2 and mediates the deregulation of p53 homeostasis. Virology (2009) 0.81
Reverse micelle-encapsulated recombinant baculovirus as an oral vaccine against H5N1 infection in mice. Antiviral Res (2010) 0.80
Deletion of the aceE gene (encoding a component of pyruvate dehydrogenase) attenuates Salmonella enterica serovar Enteritidis. FEMS Immunol Med Microbiol (2011) 0.80
Immune responses to baculovirus-displayed enterovirus 71 VP1 antigen. Expert Rev Vaccines (2013) 0.80
Enhanced replication of porcine circovirus type 2 (PCV2) in a homogeneous subpopulation of PK15 cell line. Virology (2007) 0.79
A novel baculovirus vector shows efficient gene delivery of modified porcine reproductive and respiratory syndrome virus antigens and elicits specific immune response. Vaccine (2013) 0.79
Development of a sensitive and specific epitope-blocking ELISA for universal detection of antibodies to human enterovirus 71 strains. PLoS One (2013) 0.79
Development of an ELISA using a recombinant 41 kDa partial protein (P45N') for the detection of Riemerella anatipestifer infections in ducks. Vet Microbiol (2002) 0.79
Inhibition of porcine circovirus type 2 replication in mice by RNA interference. Virology (2006) 0.79
Evaluation of a Subunit H5 Vaccine and an Inactivated H5N2 Avian Influenza Marker Vaccine in Ducks Challenged with Vietnamese H5N1 Highly Pathogenic Avian Influenza Virus. Influenza Res Treat (2010) 0.79
Display of enterovirus 71 VP1 on baculovirus as a type II transmembrane protein elicits protective B and T cell responses in immunized mice. Virus Res (2012) 0.78
Development of dual-function ELISA for effective antigen and antibody detection against H7 avian influenza virus. BMC Microbiol (2013) 0.78
The VP1 protein of avian encephalomyelitis virus is a major host-protective immunogen that serves as diagnostic potential. J Virol Methods (2008) 0.78
Membrane-association properties of avian encephalomyelitis virus protein 3A. Virology (2004) 0.78
Characterization of a novel monoclonal antibody reactive against the N-terminal region of Enterovirus 71 VP1 capsid protein. J Virol Methods (2012) 0.78